| ¿µ¹® | ovarian cancer | ÇÑ±Û | ³¼Ò¾Ï |
|---|---|---|---|
| ¼³¸í | ¿©¼ºÀÇ ³¼Ò¿¡ ¹ß»ýÇÏ´Â ¾Ï. ºÎÀΰúÁ¾¾çÀ¸·Î¼ 50¼¼ ÀÌ»ó ¿©¼º¾Ç¼ºÁ¾¾çÀÇ ¾à 18%¸¦ Â÷ÁöÇÑ´Ù. Á¾¾çÀº ´ë°³ º¹ºÎ ±í¼÷È÷ À§Ä¡ÇϹǷΠÁ¾¾çÀÌ ¸¹ÀÌ ÁøÇàµÈ »óÅ¿¡¼ ¹ß°ßµÇ´Â ¼ö°¡ ¸¹À¸¸ç, ¶ÇÇÑ Á¾¾çÀÇ Ãʱ⿡´Â Áõ»óÀÌ °ÅÀÇ ¾ø´Â °æ¿ì°¡ ¸¹¾Æ ´õ¿í Á¶±â¹ß°ßÀÌ ¾î·Æ´Ù. ¾ÆÁÖ ´Ù¾çÇÑ Á¾·ùÀÇ ¾ÏÀÌ ¹ß»ýÇϸç, ¿¹Èĵµ °¢±â ±× Á¾¾çÀÇ Á¾·ù¿¡ µû¶ó ´Ù¸£´Ù. ´ëÇ¥ÀûÀÎ ¾ÏÀ¸·Î À强³¶»ù¾ÏÁ¾(serous cystadenocarcinoma), Á¡¾×³¶»ù¾ÏÁ¾(mucinous cystadenocarcinoma), Á¾ÀÚ¼¼Æ÷Á¾(germinoma µîÀÌ ÀÖ´Ù. Ä¡·á´Â ¼ö¼úÀû Ä¡·á°¡ ¼±ÇàµÇ¾î¾ß ÇÏÁö¸¸, ¸¹ÀÌ ÁøÇàµÇ¾î ÀÌ¹Ì ´Ù¸¥ Á¶Á÷À¸·Î ÀüÀ̰¡ ÀÌ·ç¾îÁø »óÅ¿¡¼´Â ÈÇпä¹ýÀÌ ¼±ÅÃÀûÀ¸·Î »ç¿ëµÈ´Ù. |
||
| ¿µ¹® | cancer | ÇÑ±Û | ¾Ï |
|---|---|---|---|
| ¼³¸í | ³¡¾øÀÌ ºÐ¿À» ÇÏ¿© Ç÷¾×À̳ª ¸²ÇÁ°üÀ» ÅëÇÏ¿© ´Ù¸¥ Àå±â¿¡±îÁö ÀüÆÄµÉ ¼ö ÀÖ´Â ¼¼Æ÷ÀÇ µ¢¾î¸®. Áï ¾Ç¼º ½Å»ý¹°À» ¸»ÇÑ´Ù. ½Å»ý¹°Àº ¾Ç¼º°ú ¾ç¼ºÀÌ Àִµ¥, ¾Ç¼ºÀÏ °æ¿ì¿¡´Â ¼ºÀåÀÌ ¸Å¿ì ºü¸£°í Ç÷¾×À̳ª ¸²ÇÁ°üÀ» ÅëÇØ¼ ¸Ö¸® ´Ù¸¥ ¶³¾îÁø Àå±â·Î ¾Ï¼¼Æ÷ÀÇ ÀüÆÄ°¡ °¡´ÉÇÏ¿© ´Ù¸¥ Àå±â¿¡µµ ¾ÏÀ» ÀüÀÌÇϸç, ¾ç¼ºÀº õõÈ÷ ÀÚ¶ó°í ´Ù¸¥°÷À¸·Î ÀüÀ̰¡ »ý±âÁö ¾Ê´Â´Ù. ¾ÏÀº ¾ÏÁ¾°ú À°Á¾ÀÇ µÎ °¡Áö·Î ³ª´ ¼ö°¡ ÀÖ´Ù. ¾ÏÁ¾À̶õ »óÇǼ¼Æ÷ÀÇ °úµµÇÑ Áõ½Ä¿¡ ÀÇÇÑ ¾Ç¼º½Å»ý¹°À» À̸£´Â ¸»À̰í À°Á¾À̶õ ºñ»óÇǼº¼¼Æ÷ ƯÈ÷ Áß°£¿±¼¼Æ÷(¹ß»ý´ç½Ã¿¡ Áß°£¿±¿¡ ÇØ´çÇÏ´Â Á¶Á÷À¸·Î ¹ß»ýÈÄ¿¡ Á¶Á÷»çÀÌ¿¡ ºÐÆ÷ÇÏ¸é¼ Á¶Á÷À» ÁöÁöÇÏ´Â ¿ªÇÒÀ» ÇÏ´Â °áÇÕÁ¶Á÷, Ç÷°ü, ¸²ÇÁ°ü µîÀÌ µÈ´Ù)ÀÇ °úµµÇÑ Áõ½Ä¿¡ ÀÇÇÑ ¾Ç¼º ½Å»ý¹°À» À̸£´Â ¸»ÀÌ´Ù. |
||
| ¿µ¹® | cancer surgery | ÇÑ±Û | ¾Ï ¼ö¼ú |
|---|---|---|---|
| ¼³¸í | ¾ÏÀÇ 4´ë Ä¡·á¹ýÀº ¿Ü°úÀû ¼ö¼ú¿ä¹ý, ¹æ»ç¼± Ä¡·á¹ý, Ç×¾Ï ÈÇпä¹ý, ¸é¿ª¿ä¹ý µîÀ» ¸»Çϸç ÀÌÁß ¼ö¼ú¿ä¹ý°ú ¹æ»ç¼± ¿ä¹ýÀº ±¹¼ÒÀû ¿ä¹ýÀ¸·Î¼ ¾Ï¼¼Æ÷°¡ ¿ø¹ßÀå±â(óÀ½ ¾ÏÀÌ ¹ß»ýÇÑ Àå±â)³ª ±¹¼Ò ¸²ÇÁÀý±îÁö ±¹ÇѵǾî ÀÖ´Â Á¦ 1, 2±â ¾ÏÀÇ Ä¡·á¿¡ »ç¿ëµÈ´Ù. ÈÇпä¹ý°ú ¸é¿ª¿ä¹ýÀº Àü½Å¿ä¹ýÀ¸·Î¼ Á¦ 3, 4±â ¾Ï¿¡ ÁÖ·Î »ç¿ëµÇ¸ç, 1, 2±â ¾ÏÀÇ Ä¡·á ÈÄ ´«¿¡ º¸ÀÌÁö ¾Ê°Ô ³²¾Æ ÀÖÀ» ¼ö ÀÖ´Â ÀÜ·ù¾Ï¼¼Æ÷³ª ¹Ì¼¼ÀüÀÌ ¾Ï¼¼Æ÷ÀÇ ¿ÏÀüÆÄ±«, »ç¸êÀ» À§ÇØ »ç¿ëµÈ´Ù. ¹éÇ÷º´, ¸²ÇÁÁ¾°ú °°ÀÌ ÈÇпä¹ýÁ¦¿¡ Àß µè´Â Ç÷¾×¾Ï, ¸²ÇÁÁ¾°ú °íȯÁ¾°ú °°ÀÌ ¹æ»ç¼± Ä¡·á¿¡ Àß µè´Â ¾ÏÀ» Á¦¿ÜÇÑ ´ëºÎºÐÀÇ °íÇü¾Ï(solid tumor)ÀÎ À§Ã¢ÀÚ°ü¾Ï, °£¾Ï, ÀÌÀÚ¾Ï, À¯¹æ¾Ï, °©»ó»ù¾Ï, Æó¾Ï, Èæ»öÁ¾, ¿¬Á¶Á÷¾Ï, »ÀÀ°Á¾, ħ»ù¾Ï µîÀº ¸ðµÎ ¼ö¼ú¿ä¹ýÀ¸·Î Ä¡·áÇÏ¿©¾ß ÇÑ´Ù. ¾Ï¼ö¼úÀÇ ±âº»¿øÄ¢: ¾Ï¼ö¼úÀÇ 3°¡Áö ±âº»¿ä°ÇÀº ¾ÈÀü¼º, ±ÙÄ¡¼º, ±â´Éº¸Á¸¼ºÀÌ¸ç ¾Ï¼ö¼ú½Ã¿¡´Â ¾Ïº´Å͸¦ µÇµµ·Ï Á¶½ÉÇØ¼ Àû°Ô ¸¸Áö¸é¼ ¼ö¼úÇÏ°í ¾Ïº´Å͸¦ °ø±ÞÇÏ´Â µ¿Á¤¸Æ°ú ¸²ÇÁ°üÀ» ¸ÕÀú °áÂûÇÏ¿© ¾Ïº´ÅͰ¡ ÆÛÁö´Â °ÍÀ» ¹æÁöÇÑ´Ù. ¾Ï¼ö¼úÀÇ ¸ñÇ¥´Â ±ÙÄ¡Àû ÀýÁ¦¼ö¼ú(radical surgery)ÀÌ´Ù. ±×·¯³ª À̰ÍÀÌ ºÒ°¡´ÉÇÑ È¯ÀÚ¿¡¼´Â ÃâÇ÷, Æó»ö, õ°ø µîÀÇ ÇÕº´ÁõÀÌ ¹ß»ýÇßÀ»¶§ ±¸±Þ¸ñÀûÀ¸·Î ȤÀº Áö¼ÓÀû µ¿ÅëÀÌ ÀÖÀ»¶§ »ýȰ³»¿ëÀÇ ÁúÀû °³¼±À» À§ÇÏ¿© °í½ÄÀû ¼ö¼ú(palliative surgery)À» ÇÑ´Ù. ±×¸®°í ¾ÏÀÇ Á¤È®ÇÑ Áø´Ü°ú ÁøÇ൵ÀÇ °áÁ¤À» À§ÇÑ Áø´ÜÀû ¼ö¼ú(diagnostic surgery)ÀÌ ÀÖ´Ù. |
||
| ¿µ¹® | breast cancer | ÇÑ±Û | À¯¹æ¾Ï |
|---|---|---|---|
| ¼³¸í | À¯¹æÀº Áö¹æÁ¶Á÷°ú º»·¡ÀÇ ¸ñÀûÀÎ Á£À» »ý»êÇÏ´Â »ùÁ¶Á÷, ±×¸®°í ÀÌ »ùÁ¶Á÷¿¡¼ »ý»êÇÑ Á£À» ¹Û¿¡±îÁö ³»º¸³»´Â °üÁ¶Á÷, ±×¸®°í ÀÌ »ùÁ¶Á÷°ú °üÁ¶Á÷ÀÇ ÁÖÀ§¸¦ µÑ·¯½Î°í ÀÖÀ¸¸é¼ À̰͵éÀÇ ¸ð¾çÀ» À¯ÁöÇØÁÖ´Â °£Áú·Î ÀÌ·ç¾îÁø´Ù. À¯¹æ¾ÏÀ̶õ »ùÁ¶Á÷°ú °üÁ¶Á÷¿¡¼ ±â¿øÇÏ´Â Á¾¾çÀ» ¸»ÇÑ´Ù. À¯¹æ¾ÏÀ» ¹ß»ý½Ãų ¼ö ÀÖ´Â À§ÇèÀÎÀÚ´Â ¿©·¯ °¡Áö°¡ ¹àÇôÁ® ÀÖ´Ù. ±×Áß¿¡¼ ´ëÇ¥ÀûÀÎ °ÍÀº ´ÙÀ½°ú °°´Ù. 1.À¯ÀüÀû ¿äÀΣ°¡Á· Áß¿¡¼ À¯¹æ¾Ï¿¡ °É¸° »ç¶÷ÀÌ ÀÖÀ¸¸é À¯¹æ¾ÏÀÇ ¹ß»ýÈ®·üÀÌ ¾ÆÁÖ ³ô¾ÆÁø´Ù. 2.¿¡½ºÆ®·Î°Õ¿¡ Àå±âÀûÀ¸·Î ¸¹ÀÌ Æø·ÎµÇ´Â °æ¿ì£¿¡½ºÆ®·Î°ÕÀº ¿©¼ºÈ£¸£¸óÀ¸·Î ¿©¼º¿¡¼ Á¤»óÀûÀ¸·Î »ý¸®ÀÇ Áֱ⿡ µû¶ó Áõ°¨À» µÇÇ®ÀÌÇÑ´Ù. ÀÌ ¿¡½ºÆ®·Î°ÕÀº À¯¹æÀÇ Á¥»ùÁ¶Á÷°ú °üÁ¶Á÷ÀÇ Áõ½Ä°ú ¼ºÀå¿¡ °ü°èÇÑ´Ù. ±×¸®°í ÀÌ ¿¡½ºÆ®·Î°Õ¿¡ ¸¹ÀÌ Æø·ÎµÇ´Â »ç¶÷Àº À¯¹æ¾ÏÀÇ È®·üÀÌ ³ô´Ù. ¿ÜºÎ¿¡¼ ¿¡½ºÆ®·Î°ÕÀÇ Á¦Á¦¸¦ Ä¡·á¸ñÀûÀ¸·Î Åõ¿©ÇÒ °æ¿ì¿¡ À¯¹æ¾ÏÀÇ ¹ß»ýÈ®·üÀº Á¤»óÀο¡¼ º¸´Ù ÇöÀúÇÏ°Ô ³ô¾ÆÁø´Ù. ±×¸®°í ¾ÆÀ̸¦ ³ºÁö ¾Ê°í Æò»ýÀ» »ç´Â ¿©ÀÚÀÇ °æ¿ì¿¡ ÀÓ½ÅÀ» ÇÏ°í ¾ÆÀ̸¦ ³ºÀº ¿©ÀÚ¿¡ ºñÇØ¼ ¿¡½ºÆ®·Î°Õ¿¡ ¸¹ÀÌ Æø·Î°¡ µÇ¹Ç·Î(ÀӽŽÿ¡´Â ºñÀӽŽú¸´Ù ¿¡½ºÆ®·Î°Õ¿¡ Àû°Ô Æø·Î°¡ µÈ´Ù)À¯¹æ¾ÏÀÇ È®·üÀÌ ³ô´Ù. 3.ȯ°æÀû ¿äÀΣÁö¹æÁú ¼·ÃëÀÇ Áõ°¡, ¼úÀÇ ¼·Ãë µîÀº À¯¹æ¾ÏÀÇ È®·üÀ» ³ôÀδÙ. À¯¹æ¾ÏÀÇ Áõ»óÀ¸·Î °¡Àå ¸¹Àº °ÍÀº ¾ÆÇÁÁö ¾ÊÀº À¯¹æÀÇ µ¢¾î¸®ÀÌ´Ù. ±×¸®°í À¯µÎ¿¡¼ ºÐºñ¹°ÀÌ ³ª¿À°Å³ª, À¯¹æÀÇ ÇǺκ¯È µîÀÌ À¯¹æ¾ÏÀÇ ÈçÇÑ Áõ»óÀÌ´Ù. Ä¡·á´Â À¯¹æÀÇ ÀýÁ¦¼úÀÌ °¡Àå È¿°úÀûÀÎ Ä¡·á¹ýÀ¸·Î µÇ¾îÀÖ´Ù. ±×¸®°í À̰Ϳ¡ ´õÇÏ¿© ¹æ»ç¼± Ä¡·á³ª Ç×¾ÏÁ¦¿ä¹ýµµ È¿°ú°¡ ÀÖ´Â °ÍÀ¸·Î µÇ¾îÀÖ´Ù. ¶Ç ¿¡½ºÆ®·Î°ÕÀÇ °úÀ×°ú °ü°è°¡ ÀÖ´Â Á¾¾çÀÏ °æ¿ì¿¡´Â ¿¡½ºÆ®·Î°ÕÀÇ È¿°ú¸¦ Â÷´ÜÇÏ´Â ¾à¹°µµ È¿°ú°¡ ÀÖ´Ù. |
||
| ¿µ¹® | cervix cancer | ÇÑ±Û | Àڱøñ¾Ï, ÀڱðæºÎ¾Ï |
|---|---|---|---|
| ¼³¸í | ÀÚ±ÃÀÇ ¸ñÀº ÀÚ±ÃÀÌ Áú°ú ¿¬°áµÈ ºÎÀ§·Î ÀÚ±ÃÀÇ ÀÔ±¸¿¡ ÇØ´çÇÏ´Â ºÎÀ§ÀÌ´Ù. À̰÷ÀÇ »óÇǼ¼Æ÷¿¡¼ ¹ß»ýÇÏ´Â ¾ÏÀ» Àڱøñ¾ÏÀ̶ó°í ÇÑ´Ù. Àڱøñ¾ÏÀÇ ¹ß»ýÀ» »ìÆìº¸¸é ÀڱøñÀÇ »óÇǼ¼Æ÷°¡ ¿©·¯ °¡Áö Àڱؿ¡ ÀÇÇØ¼ Á¤»ó¼¼Æ÷¿Í Â÷À̳ª´Â ¾Ï¼ºº¯È¸¦ ÇÑ ¼¼Æ÷°¡ »ý±â°Ô µÈ´Ù. ÀÌ ¾Ï¼ºº¯È¸¦ ÇÑ ¼¼Æ÷´Â óÀ½¿¡´Â ÀڱøñÀÇ »óÇǼ¼Æ÷ÃþÀÇ ÀϺθ¦ ÀÌ·ç°í ÀÖ°Ô µÈ´Ù. ±×·¯´Ù°¡ Á¡Á¡ ´õ ÁøÇàÀÌ µÇ¸é ¾Ï¼º¼¼Æ÷°¡ Àڱøñ »óÇǼ¼Æ÷ÀÇ ¸ðµç ÃþÀ» ²Ëä¿ì°Ô µÈ´Ù. ±×¸®°í °è¼Ó ÁøÇàÇÏ¸é »óÇǼ¼Æ÷ÀÇ ¸Ç ¹Ø¿¡ ÀÖ´Â ¹Ù´Ú¸·À» ¶Õ°í ¹öÆÀÁ¶Á÷À¸·Î ħÀ±ÇØ µé¾î°¡°Ô µÈ´Ù. ¾Ï¼ºº¯È¸¦ ÇÑ ¼¼Æ÷°¡ ÀÚ±ÃÀÇ »óÇÇÃþÀÇ ÀϺθ¦ ä¿ì´Â °ÍÀ» ÀڱøñÇü¼ºÀÌ»ó(cervical dysplasia)¶ó°í ÇÏ°í ¾Ï¼ºº¯È¸¦ ÇÑ ¼¼Æ÷°¡ ÀÚ±ÃÀÇ »óÇÇÃþÀ» ¸ðµÎ ä¿ö¹ö·Á Á¤»óÀûÀÎ ¼¼Æ÷°¡ ¾ø´Â °æ¿ì¸¦ »óÇdz»¾ÏÁ¾(carcinoma in situ)¶ó°í ÇÑ´Ù. ±×¸®°í ¹Ù´Ú¸·À» ¶Õ°í ¹ØÀÇ ¹öÆÀÁ¶Á÷À¸·Î ħ¹üÇØ ³ª°¡´Â °æ¿ì¸¦ ħÀ±¾Ï(invasive cancer)¶ó°í ÇÑ´Ù. Àڱøñ¾ÏÀº ¿©·¯ ¸íÀÇ »ó´ë¿Í ¼º°ü°è¸¦ °¡Áö´Â ¿©ÀÚ, ±×¸®°í ù ¼º°æÇèÀÇ ³ªÀ̰¡ ¾î¸° ¿©ÀÚ¿¡°Ô¼ ÈçÇÏ°í ¶Ç »çȸÀû, °æÁ¦Àû ¼öÁØÀÌ ³·Àº »ç¶÷¿¡°Ô¼ Àß °É¸®´Â °ÍÀ¸·Î µÇ¾î ÀÖ´Ù. ÀÌ·± °ÍÀ¸·Î ¹Ì·ç¾î Àڱøñ¼¼Æ÷ÀÇ ¾Ï¼ºº¯È¿¡´Â ¼ºº´°ú °°Àº °¨¿°ÀÌ Áß¿äÇÒ °ÍÀ¸·Î »ý°¢µÇ°í, ¶Ç ¸î°¡Áö ¹ÙÀÌ·¯½ºÀÇ °¨¿°ÀÌ Àڱøñ¾ÏÀÇ ¿øÀÎÀ̶ó´Â °ÍÀÌ ¹àÇôÁ® ÀÖ´Ù. Àڱøñ¾ÏÀÇ Áø´Ü¹æ¹ýÀ¸·Î´Â Áú¼¼Æ÷°Ë»ç, ÄÝÆ÷½ºÄÚÇÇ, »ý°Ë(biopsy) µîÀÌ ÀÖ´Ù. ¼¼Æ÷°Ë»ç¶õ Á¶±âÁø´Ü ¸ñÀûÀ¸·Î °¡Àå ¸¹ÀÌ »ç¿ëµÇ´Â ¹æ¹ýÀ¸·Î ¼ØºÀÀ¸·Î ÀڱøñÀ»¸¦ ¹®Áú·¯¼ Àڱøñ»óÇǼ¼Æ÷¸¦ ¾ò°í À̰ÍÀ» Çö¹Ì°æÀ¸·Î °üÂûÇÏ¿© »óÇǼ¼Æ÷ÀÇ º¯È¸¦ º¸´Â °ÍÀÌ´Ù. ÄÝÆ÷½ºÄÚÇǶõ ÀÚ±ÃÀÇ ¸ñÀ» 4~10¹è Á¤µµ È®´ëÇØ¼ º¸´Â ÀÏÁ¾ÀÇ È®´ë°æ°Ë»çÀ¸·Î Àڱøñ¾ÏÀ¸·Î ÀÎÇÑ ÀڱøñÀÇ º´Àûº¯È¸¦ °üÂûÇÏ¿© Áø´ÜÇÏ´Â °ÍÀÌ´Ù. »ý°Ë¶õ Áø´ÜÀ» À§Çؼ Á÷Á¢ ÀڱøñÀÇ Á¶Á÷À» ¶¼¾î äÃëÇÏ¿© Çö¹Ì°æÀ¸·Î °üÂûÇÏ¿© Áø´ÜÇÏ´Â °ÍÀ¸·Î °¡Àå Á¤È®ÇÑ Áø´Ü¹ýÀÌ´Ù. Ä¡·á·Î´Â º´ÀÇ ÁøÇàÁ¤µµ¿¡ µû¶ó ´Ù¸£°ÚÁö¸¸ ¾ÏÀÇ ÁøÇàÀÌ °ÅÀÇ ¾ø¾î Çü¼ºÀÌ»óÀ̳ª Á¦ÀÚ¸®¾ÏÁ¾ ¶Ç´Â ¾ÆÁÖ Á¶±Ý ħÀ±ÇÏ¿´À» °æ¿ì¿¡´Â ¼ö¼úÀû¿ä¹ýÀ¸·Î ÀÚ±ÃÀ» ÀûÃâÇÏ´Â °ÍÀÌ Ä¡·áÀÇ ¿øÄ¢ÀÌ°í ¸¹Àº ÁøÇàÀ» º¸¿© ´Ù¸¥ Á¶Á÷À¸·Î ¾ÏÀÇ Ä§À±ÀÌ ÀÖÀ» °æ¿ì¿¡´Â ¹æ»ç¼± Ä¡·á¸¦ ¿øÄ¢À¸·Î ÇÑ´Ù. |
||
| AFP | Alpha(¥á) Feto-Protein [HP 1826, 1858, 1859, 2265] ; Oncofetal Antigens &nbs... |
|---|---|
| CEA | Carcino-Embryonic Antigen [HP 1825-6] ; Oncofetal Antigens ; Glycopro... |
| CC | calcaneal-cuboid; calcium cyclamate; cardiac catheterization; cardiac contusion; cardiac cycle; card... |
| ICR | [distance between] iliac crests; Institute for Cancer Research; Institute for Cancer Research [mouse... |
| MBC | male breast cancer; maximal bladder capacity; maximal breathing capacity; metastatic breast cancer; ... |
| CALGB | Cancer and Leukaemia Group B |
|---|---|
| A-MuL V | Abelson murine leukaemia virus |
| ALL | Acute Lymphocytic Leukaemia |
| AML | Acute Myeloblastic Leukaemia |
| AML | Acute Myelogenous Leukaemia |
| cancer, leukaemia | Leukaemia is a cancer of the white blood cells. Leukaemias are grouped by how quickly the disease develops (acute or chronic) as well as by the type of blood cell that is affected. People with leukaemia are at significantly increased risk for developing infections, anaemia, and bleeding. Diagnosis of leukaemia is supported by findings of the medical history and examination, and examining blood under a microscope. Leukaemia cells can be detected and further classified with a bone marrow aspiration and/or biopsy. most patients with leukaemia are treated with chemotherapy. Some patients also may have radiation therapy and/or bone marrow transplantation. (12 Dec 1998) |
|---|
| abelson leukaemia virus | A defective murine leukaemia virus capable of transforming lymphoid cells and producing a rapidly progressing lymphoid leukaemia after superinfection with friend, moloney, or rauscher virus. (12 Dec 1998) |
|---|---|
| Abelson murine leukaemia virus | A retrovirus belonging to the Type C retrovirus group subfamily (family Oncovirinae) which is associated with leukaemia and produces in vitro transformation of mouse cells. (05 Mar 2000) |
| accelerated phase of leukaemia | Refers to chronic myelogenous leukaemia that is progressing. The number of immature, abnormal white blood cells in the bone marrow and blood is higher than in the chronic phase, but not as high as in the blast phase. (12 Dec 1998) |
| acute granulocytic leukaemia | <haematology> A form of leukaemia which is characterised by the proliferation of immature white blood cells (granulocytes) in the bloodstream. Occurs primarily in adults and in infants under 1 year of age. Complications include abnormal bleeding and susceptibility to infections. Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains. Treatment includes chemotherapy and/or bone marrow transplant. Origin: Gr. Haima = blood (27 Sep 1997) |
| acute leukaemia | <haematology> A rapidly progressive cancer of the blood of sudden onset and characterised by the uncontrolled proliferation of immature blood cells which take over the bone marrow and spill into the blood stream. If left untreated is fatal within a few weeks or months. See: acute lymphoblastic leukaemia, acute myeloid leukaemia. Origin: Gr. Haima = blood (11 Nov 1997) |
| acute lymphoblastic leukaemia | <haematology> A rapidly progressing cancer of the blood affecting the type of white blood cell known as lymphocytes. Approximately 650 new cases are diagnosed every year in the UK and it is the most common form of childhood leukaemia. Acronym: ALL Origin: Gr. Haima = blood (11 Nov 1997) |
| acute lymphocytic leukaemia | <radiology> 95% of cases of leukaemia in children, bone changes in 50-70% of kids (vs. 10% in adults); seen as early as 1 month after onset of symptoms, wrists and knees most commonly affected, bony defects: metaphyseal radiolucent bands! (similar findings in scurvy, JRA, syphilis), osteolytic lesions, periosteal reaction, osteosclerosis (12 Dec 1998) |
| acute monocytic leukaemia | <haematology> The most common translocation in this disorder of poorly differentiated monocytic cells involves chromosome region 11q in a large percentage of cases. The translocation involves a cellular oncogene, c-ets which is mapped to the 11q23-24 region. The most common translocations reported are t(6;11), t(9;11), t(11;17) and t(11;19), of which t(9;11) (p21-22;q23) is by far the most frequently detected and implicated in acute myeloid leukaemia. The cells express CD14 surface antigen, which is diagnostic of monocytic cells. Acronym: AML Classification: FAB M5 (07 Apr 1998) |
| acute myeloblastic leukaemia | <haematology> A rapidly progressing cancer of the blood affecting immature cells of the bone marrow, usually of the white cell population. It is much more common in adults than in children. Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains. Treatment includes chemotherapy and/or bone marrow transplant. This leukaemia demonstrates granulocyte differentiation, eosinophilia and Auer rods and is associated with a reciprocal translocation between 8 and 21 (q22;q22), which is the most common translocation in acute myeloid leukaemia and is found more often in younger patients than in older patients. The oncogene involved in this translocation is AML1, which can be detected by Southern blot. Numerical abnormalities, particularly monosomy-7, trisomy-4, trisomy-8, trisomy-21, -Y, monosomy-7 and deletions of the long arms of chromosomes 5 and 7 are quite common in all acute myeloid leukaemia and not restricted to any one FAB classification. Many of these abnormalities are observed at diagnosis and at later stage disease, particularly after chemotherapy. Prognosis is generally more favorable than in FAB-M2 patients showing no translocation, because the latter patients show better remission rates for longer periods of time. Immunophenotyping is useful in diagnosis and expression of one or more of the myeloid antigens CD13, CD14 or CD33 must be detected to make a diagnosis of acute myeloid leukaemia. Acronym: AML Incidence: 2,000 new cases per year in the UK. Origin: Gr. Haima = blood (07 Apr 1998) |
| acute myelogenous leukaemia | <haematology> A rapidly progressing cancer of the blood affecting immature cells of the bone marrow, usually of the white cell population. It is much more common in adults than in children. Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains. Treatment includes chemotherapy and/or bone marrow transplant. This leukaemia demonstrates granulocyte differentiation, eosinophilia and Auer rods and is associated with a reciprocal translocation between 8 and 21 (q22;q22), which is the most common translocation in acute myeloid leukaemia and is found more often in younger patients than in older patients. The oncogene involved in this translocation is AML1, which can be detected by Southern blot. Numerical abnormalities, particularly monosomy-7, trisomy-4, trisomy-8, trisomy-21, -Y, monosomy-7 and deletions of the long arms of chromosomes 5 and 7 are quite common in all acute myeloid leukaemia and not restricted to any one FAB classification. Many of these abnormalities are observed at diagnosis and at later stage disease, particularly after chemotherapy. Prognosis is generally more favorable than in FAB-M2 patients showing no translocation, because the latter patients show better remission rates for longer periods of time. Immunophenotyping is useful in diagnosis and expression of one or more of the myeloid antigens CD13, CD14 or CD33 must be detected to make a diagnosis of acute myeloid leukaemia. Acronym: AML Incidence: 2,000 new cases per year in the UK. Origin: Gr. Haima = blood (07 Apr 1998) |
| acute myeloid leukaemia | <haematology> A rapidly progressing cancer of the blood affecting immature cells of the bone marrow, usually of the white cell population. It is much more common in adults than in children. Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains. Treatment includes chemotherapy and/or bone marrow transplant. This leukaemia demonstrates granulocyte differentiation, eosinophilia and Auer rods and is associated with a reciprocal translocation between 8 and 21 (q22;q22), which is the most common translocation in acute myeloid leukaemia and is found more often in younger patients than in older patients. The oncogene involved in this translocation is AML1, which can be detected by Southern blot. Numerical abnormalities, particularly monosomy-7, trisomy-4, trisomy-8, trisomy-21, -Y, monosomy-7 and deletions of the long arms of chromosomes 5 and 7 are quite common in all acute myeloid leukaemia and not restricted to any one FAB classification. Many of these abnormalities are observed at diagnosis and at later stage disease, particularly after chemotherapy. Prognosis is generally more favorable than in FAB-M2 patients showing no translocation, because the latter patients show better remission rates for longer periods of time. Immunophenotyping is useful in diagnosis and expression of one or more of the myeloid antigens CD13, CD14 or CD33 must be detected to make a diagnosis of acute myeloid leukaemia. Acronym: AML Incidence: 2,000 new cases per year in the UK. Origin: Gr. Haima = blood (07 Apr 1998) |
| acute non-lymphocytic leukaemia | <haematology> A form of leukaemia which is characterised by the proliferation of immature bone marrow precursor cells in the marrow and immature white blood cells (granulocytes) in the bloodstream. Occurs primarily in adults and in infants under 1 year of age. Complications include abnormal bleeding and susceptibility to infections. Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains. Trisomy-8 is the most common cytogenetic abnormality observed, followed by monosomy-7 and monosomy-5. Approximately 8% of cases show trisomy-8, mostly in AML (M1), AM (M4) and acute monocytic leukaemia (M5). Many pre-leukaemic conditions, acute non-lymphocytic leukaemia and secondary leukemia show monosomy-7 or deletion of the long arm of chromosome 7. Treatment includes chemotherapy and/or bone marrow transplant. Acronym: ANLL Incidence: 2.5 cases per 100,000 (all ages). Origin: Gr. Haima = blood (07 Apr 1998) |
| acute promyelocytic leukaemia | Leukaemia presenting as a severe bleeding disorder, with infiltration of the bone marrow by abnormal promyelocytes and myelocytes, a low plasma fibrinogen, and defective coagulation. (05 Mar 2000) |
| adult T-cell leukaemia | Lymph nodes show a mixture of small and large atypical cells which are polymorphic and express nuclear pleiomorphism. Adult T-cell leukaemia is caused by HTLV-1 and is rare in the US and Europe but common in Japan. Tumour cells express CD2, CD3, CD5 and lack CD7. The most common chromosome change reported in adult T-cell leukaemia is presence of the 14q + marker (05 Mar 2000) |
| aleukaemic leukaemia | Leukaemia in which abnormal (or leukaemic) cells are absent in the peripheral blood. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|